Abstract
eliminate in-stent restenosis in selected simple lesions (FIM. RAVEL trials). The aim of this study is to investigate the efficacy of SES in the treatment of bifurcation lesions. Methods: Since ld” April 2002 it is the policy of our institution to utilize the SES as a device of choice for all percutaneous interventions, with no clinical or anatomical exclusion criteria. The patients with bifurcation lesions are being included in this study. The follow-up angiography will be performed at 6 months after procedure. Results: Up to 161h August 2002, 44 patients with 44 bifurcation lesions have been treated with SES. The mean age was 61 years old and 13 patients (29.5%) were diabetic. All patients underwent SES deployment in both vessels. The baseline QCA results are present in the table. So far, there has been one target lesion revascularization 5 weeks after procedure, however it is noteworthy that the restenosis occurred at the ostium of a side branch that was not covered with SES. The clinical outcomes and follow-up QCA results will be available at the time of presentation.Conclusions In this study, the impact of sirolimus-eluting stents on the outcome of patients with bifurcation lesions in the “real world” experience will be reported.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
